Ebvallo Atara Biotherapeutics Provides Regulatory Update on Ebvallo (tabelecleucel)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that…
Read more
